We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Stockal+Disclaimer.pdf
43 own
23 watching
Current Price
$30.48
$0.9
(3.04%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
960.73M
52-Week High
42.20000
52-Week Low
8.79000
Average Volume
2.04M
Dividend Yield
--
P/E Ratio
--
Market Capitalization960.73M52-Week High42.2000052-Week Low8.79000Average Volume2.04MDividend Yield--P/E Ratio--What does the Stockal+Disclaimer.pdf do?
Cassava Sciences, Inc. is a clinical-stage biopharmaceutical company focused on neuroscience. The Company's science is based on stabilizing, but not removing, a critical protein in the Alzheimer’s brain. Its scientific approach for the treatment of Alzheimer's disease seeks to simultaneously suppress both neurodegeneration and neuroinflammation. It has two biopharmaceutical assets under development: Simufilam and SavaDx. Simufilam, its lead therapeutic product candidate, is an oral treatment for Alzheimer’s disease dementia. Simufilam targets an altered form of a protein called filamin A (FLNA) in the Alzheimer’s brain. It is conducting two randomized placebo-controlled Phase III clinical trials of oral simufilam in patients with Alzheimer’s disease dementia. SavaDx, its lead investigational diagnostic product candidate, is a way to detect the presence of Alzheimer’s disease from a small sample of blood. SavaDx is a research-use only, non-safety related exploratory biomarker.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
Globe Newswire
1 year ago
CHART 1
Decline in Cognition Scores, FAS
CHART 2
Decline in Cognition Scores, patients with mild Alzheimer's
Figure 1
Historical declines on ADAS-Cog over 18 months in Alzheimer's disease (MMSE 20-30), placebo arms vs simufilam treatment.
Simufilam Slowed Cognitive Decline by 38% Versus ...
Globe Newswire
1 year ago
Overactive mTOR Plays a Key Role in Aging and Alzheimers Disease.Simufilam Suppresses Overactive mTOR, Suggesting a Beneficial Drug Effect.Research is Published in Frontiers in Aging, a Peer-reviewed Journal. AUSTIN, Texas, June 27, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a ...
Globe Newswire
1 year ago
Publication Reviews Certain Receptor-Protein Interactions. Provides Overview of Basic Science Supporting Simufilam. Published in Drug Development Research, a Peer-Reviewed Journal. AUSTIN, Texas, June 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology ...
Globe Newswire
1 year ago
Over 1,244 Alzheimers patients now enrolled in Phase 3 studies of simufilam.Completion of patient enrollment for Phase 3 program still expected Q4 2023.$187.5 Million Cash and Cash Equivalents at March 31, 2023. AUSTIN, Texas, May 01, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a...
Globe Newswire
1 year ago
AUSTIN, Texas, April 26, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimers disease, today announced that Remi Barbier, President & Chief Executive Officer, has been invited to present at the 2023 H.C. Wainwright BioConnect ...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
Can Indians buy Stockal+Disclaimer.pdf shares?
How can I buy Stockal+Disclaimer.pdf shares from India?
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
What is today’s traded volume of Stockal+Disclaimer.pdf?
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
Current Price
$30.48
$0.9
(3.04%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.